New York, January 11, 2026, 06:15 EST — Market closed.
- Kenvue ended Friday down about 1%, keeping a gap to the implied value of the Kimberly-Clark offer
- The payout mixes cash and Kimberly-Clark shares, so the offer value moves with KMB day to day
- Traders are watching Kimberly-Clark earnings on Jan. 27 and a Jan. 29 shareholder meeting, with Kenvue results expected in early February
Kenvue Inc shares slipped about 1% on Friday to close at $16.83, with volume of about 57.5 million shares, Nasdaq data showed. The stock finished the week still trading below the value implied by Kimberly-Clark’s agreed buyout.
The market is shut on Sunday, but KVUE is being traded like a deal stock now. With a late-January vote on deck and earnings around the corner, the spread has become the quick read on whether investors think the transaction closes cleanly — and on time.
Kimberly-Clark and Kenvue agreed in November to merge in a cash-and-stock deal that offers $3.50 in cash and 0.14625 Kimberly-Clark shares for each Kenvue share, and the companies projected $2.1 billion of run-rate synergies while pegging the transaction at about $48.7 billion in enterprise value. Using Friday’s close for Kimberly-Clark — $97.92, down about 1% — the package implies about $17.82 per Kenvue share, leaving KVUE roughly 6% below the offer value on a simple mark-to-market basis. Kimberly-Clark CEO Mike Hsu said Kenvue is “uniquely positioned at the intersection of CPG and healthcare.” investors.kenvue.com
That gap is the merger spread — trader shorthand for the discount between a target’s stock price and what the deal is worth today. It tends to widen when investors see a higher chance of delays, a renegotiation, or a break.
One recent filing tied to the transaction said a definitive joint proxy statement/prospectus had been mailed and that both companies are seeking stockholder approval, while warning that expected benefits and timing could be derailed by regulatory, financing, integration and litigation risks.
A proxy statement said Kimberly-Clark will hold a virtual special meeting on Jan. 29, and Kenvue’s board unanimously recommends that Kenvue stockholders vote for the merger. The document also points to a second-half 2026 closing timeline, subject to approvals.
Before the vote, investors get fresh numbers from the buyer. Kimberly-Clark is scheduled to report fourth-quarter and full-year 2025 results on Jan. 27, according to its investor site.
Kenvue’s own quarterly report is expected soon after. Nasdaq lists Feb. 5 as the estimated earnings date for Kenvue, though the company has not confirmed it there.
Analysts tracked by Yahoo Finance expect Kenvue to report adjusted earnings of about $0.22 per share for the quarter, and the mean price target sits near $19, the site showed.
But the spread can move for reasons that have little to do with quarterly numbers. TD Cowen analyst Robert Moskow has said the Tylenol-related litigation risk is “hard to quantify,” and Reuters has reported the merger carries a $1.12 billion termination fee if it falls apart. Reuters
